Kazuaki Enya
Nagoya, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Increasing Orphan Drug Loss in Japan: Trends and R&D Strategy for Rare Diseases
Journal: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
Published: January 04, 2026
Evolving Research and Development Landscape for Rare Diseases: Growing Concerns Over Orphan Drug Lag in Japan.
Journal: Clinical pharmacology and therapeutics
Published: October 03, 2024
Increasing orphan drug loss in Japan: Trends and R&D strategy for rare diseases.
Journal: Drug discovery today
Published: May 28, 2023
Correction to: Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study.
Journal: Clinical and experimental nephrology
Published: January 13, 2022
Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study.
Journal: Clinical and experimental nephrology
Published: July 15, 2021
Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.
Journal: Fertility and sterility
Published: April 11, 2019
Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
Journal: Obstetrics and gynecology
Published: February 12, 2019
Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis.
Journal: Biochemical and biophysical research communications
Published: February 02, 2018
Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study.
Journal: Diabetes, obesity & metabolism
Published: February 09, 2016
Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.
Journal: Diabetes technology & therapeutics
Published: December 23, 2014
Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.
Journal: Diabetes, obesity & metabolism
Published: December 18, 2014
Last Updated: 09/26/2026